Literature DB >> 24209382

Determinants of buprenorphine treatment for opioid dependence.

Sean M Murphy1, Paul A Fishman2, Sterling McPherson3, Dennis G Dyck4, John R Roll4.   

Abstract

This study assessed the social, demographic and clinical determinants of whether an opioid-dependent patient received buprenorphine versus an alternative therapy. A retrospective cohort analysis of opioid-dependent adults enrolled in Group Health Cooperative between January 1, 2006 and December 1, 2010 was performed. Increasing the number of physicians with DATA waivers in a region and living in a relatively-populated area increased the likelihood of being treated with buprenorphine, indicating that lack of access is a potential barrier. Comorbidity also appeared to be a factor in receipt of treatment, with the effect varying by diagnosis. Finally, patients with an insurance plan allowing health services to be sought from any provider, with increased cost sharing, were significantly more likely to receive buprenorphine, implying that patient demand is a factor. Programs integrating patient education, physician training, and support from addiction specialists would be likely facilitators of increasing access to this cost-effective treatment.
© 2014.

Entities:  

Keywords:  Buprenorphine; Opioid dependence; Treatment determinants

Mesh:

Substances:

Year:  2013        PMID: 24209382     DOI: 10.1016/j.jsat.2013.09.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

1.  The Associations of Neighborhood Availability of Marijuana Dispensaries and DATA-2000 Waivered Providers with Hospital Stays Related to Opioids.

Authors:  Di Liang; Yuyan Shi
Journal:  Subst Use Misuse       Date:  2019-08-25       Impact factor: 2.164

2.  Assessing Differences in the Availability of Opioid Addiction Therapy Options: Rural Versus Urban and American Indian Reservation Versus Nonreservation.

Authors:  Katherine A Hirchak; Sean M Murphy
Journal:  J Rural Health       Date:  2016-03-14       Impact factor: 4.333

3.  Why aren't physicians prescribing more buprenorphine?

Authors:  Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2017-04-12

4.  Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.

Authors:  Madeline C Frost; Julie E Richards; John R Blosnich; Eric J Hawkins; Judith I Tsui; E Jennifer Edelman; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2022-06-03       Impact factor: 4.852

5.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Authors:  Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green
Journal:  Drug Alcohol Depend       Date:  2016-01-06       Impact factor: 4.492

6.  Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial.

Authors:  Sean M Murphy; Aimee N C Campbell; Udi E Ghitza; Tiffany L Kyle; Genie L Bailey; Edward V Nunes; Daniel Polsky
Journal:  Drug Alcohol Depend       Date:  2016-01-30       Impact factor: 4.492

7.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Authors:  Aaron D Fox; Adam Chamberlain; Nancy L Sohler; Taeko Frost; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2014-08-07

Review 8.  Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.

Authors:  Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

9.  Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.

Authors:  Sean M Murphy; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Ali Jalali; Matisyahu Shulman; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman
Journal:  Addiction       Date:  2021-05-21       Impact factor: 6.526

10.  Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.

Authors:  Marcus A Bachhuber; Cole Thompson; Ann Prybylowski; José Benitez; Silvana Mazzella; David Barclay
Journal:  Subst Abus       Date:  2018-05-04       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.